Integra LifeSciences Returns To Organic Growth After Rough Year With COVID-19
Executive Summary
Integra's first-quarter revenue was up less than 3%, year over year, but the company reported the integration of the ACell regenerative technology business is ahead of schedule
You may also be interested in...
JPM 2021: Conformis Announces ACS Knee For 2H 2021, Integra Weathers Pandemic
The annual J.P. Morgan Healthcare Conference includes presentations from many major medtech companies outlining their growth strategies and expectations for 2021. Here are some of the highlights from the final day of the meeting.
Integra Adds ACell’s Regenerative Tech As It Dumps Extremity Orthopedics
Integra will pay up to $400m for ACell to expand its wound management and soft-tissue repair product line. The deal is part of a larger restructuring plan that includes selling its orthopedics business.
NeoGenomics Bolsters Liquid Diagnostics Portfolio By Acquiring Inivata
Inivata will remain a separate liquid biopsy division alongside NeoGenomics’ growing clinical, pharma and informatics divisions.